Abbott LaboratoriesvsImmuCell

ABT and ICCC stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$107.45

Value $187B

+1.18%
ABT's page

ICCC

ImmuCell Corporation

$11.42

Value $103M

+5.19%
ICCC's page

Abbott Laboratories (ABT) has a market value of $187B and ImmuCell (ICCC) $103M. Over the last year, with dividends, ABT moved -13.7% and ICCC +75.4%. The P/E is 39.7 for ABT and 55.0 for ICCC. Dividend yield: ABT 2.35%, ICCC none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$187B

    ICCC$103M

    ABT is 1,807 times ICCC

  • Revenue, 12 months

    ABT$48.2B

    ICCC$33M

    ABT is 1,452 times ICCC

  • Net income, 12 months

    ABT$4.7B

    ICCC$1.9M

    ABT is 2,501 times ICCC

  • Operating margin

    ABT13.8%

    ICCC14.5%

    0.7 points apart

  • ROIC

    ABT6.3%

    ICCC9.8%

    3.5 points apart

  • P/E

    ABT39.7

    ICCC55.0

    ICCC is 1.4 times ABT

  • Dividend yield

    ABT2.4%

    ICCC0.0%

    2.4 points apart

  • 5-year return

    ABT-6.7%

    ICCC+16.6%

    23.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-6.7%

ICCC+16.6%

507510012520222023202420252026
Returns by period
PeriodABTWith dividendsICCCWith dividends
1 year since November 12, 2025-13.7%Price -15.8%+75.4%Price +75.4%
3 years since November 13, 2023+20.7%+6.5% a yearPrice +13.3%+106.7%+27.4% a yearPrice +106.7%
5 years since November 12, 2021-6.7%-1.4% a yearPrice -15.5%+16.6%+3.1% a yearPrice +16.6%
10 years since November 16, 2016+227.7%+12.6% a yearPrice +171.6%+119.4%+8.2% a yearPrice +119.4%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesICCCImmuCell

Valuation

ABTICCC
Valuation
Price$107.45$11.42
Market value$187B$103M
Enterprise value (EV)$214B$103M
P/E39.755.0
P/E, 5-year median33.7–
P/B3.73.2
EV/EBIT32.121.5
Free cash flow yield3.6%5.2%

Results and growth

ABTICCC
Results and growth
Revenue, 12 months$48.2B$33M
Net income, 12 months$4.7B$1.9M
Free cash flow, 12 months$6.8B$5.4M
Earnings per share, 12 months$2.69$0.19
Revenue growth, year on year5.7%4.3%
Revenue growth a year, past+5.1%over 5 years+12.5%over 5 years
EPS growth a year, past+8.3%over 5 years–

Margins and returns on capital

ABTICCC
Margins and returns on capital
Gross margin56.9%40.8%
Operating margin13.8%14.5%
Net margin9.8%5.7%
ROIC6.3%9.8%
ROE9.1%6.3%

Balance sheet

ABTICCC
Balance sheet
Cash$4.3B$7.9M
Total debt$31.2B$12M
Net debt / EBITDA3.30.0
Interest cover6.7×12.2×

Dividends and buybacks

ABTICCC
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$2.52–
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%–
Shareholder yield2.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or ICCC

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or ImmuCell?

By market value, Abbott Laboratories ($187B) is about 1,807.2 times ImmuCell ($103M), at today's prices.

How did ABT and ICCC stock do over the last 10 years?

Since November 16, 2016, ABT's price moved +171.6% and ICCC's +119.4%. With dividends: ABT +227.7% (+12.6% a year), ICCC +119.4% (+8.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or ICCC?

The dividend yield at today's price is 2.35% for Abbott Laboratories and none for ImmuCell. Over the last twelve months they paid $2.52 and – per share.

What is the P/E of ABT and ICCC?

At today's price, the P/E is 39.7 for ABT and 55.0 for ICCC. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Abbott Laboratories or ImmuCell?

Over the last twelve months, the net margin was 9.8% for Abbott Laboratories and 5.7% for ImmuCell, and the operating margin 13.8% and 14.5%. Revenue was $48.2B and $33M.

Which is the better investment, Abbott Laboratories or ImmuCell?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.